



To: Jai Medical Providers
From: ProCare Rx
Date: April 1, 2019
Subject: 1st Quarter Important Announcements

Effective immediately, the following products have been added to the formulary:

- Eliquis
- Entresto

Effective immediately, generic Harvoni (ledipasvir-sofosbuvir) and generic Epclusa (sofosbuvir-velpatasvir) have been added to the list of preferred treatments (with prior authorization) for Hepatitis C. Jai Medical Systems will continue to use the clinical criteria from Maryland Medicaid when approving all treatments, but patients must be ineligible for a preferred treatment before a non-preferred treatment will be approved. The list of preferred treatments (prior authorization still required) for Hepatitis C will now be as follows:

<u>generic Harvoni (ledipasvir-sofosbuvir)</u>	Genotypes 1,4,5,6
<u>generic Epclusa (sofosbuvir-velpatasvir)</u>	All Genotypes
Zepatier	Genotypes 1 and 4
Mavyret	All Genotypes

Providers can contact ProCare's Prior-Authorization Department at 800-555-8513 for assistance with PA requests or questions regarding clinical guidelines. Our PA Department is available Monday through Friday from 8:30 am-5:30 pm EST. For assistance with PA requests during non-business hours please contact our 24 hour customer service department at 800-213-5640.